Skip to content

Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)

Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00149266
Enrollment
167
Registered
2005-09-08
Start date
1995-07-31
Completion date
2008-12-31
Last updated
2009-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Neoplasm

Keywords

stomach neoplasms, lymph node resection, cardia, thoracotomy

Brief summary

To compare left thoraco-abdominal approach with abdominal and transhiatal approach to cardia or subcardia cancer

Detailed description

For gastric cancers with esophageal invasion (Siewert type II and III), thoraco-abdominal approach has shown better survival results than abdominal approach in retrospective analyses. However, patients having mediastinal nodal metastasis have poor prognosis and the benefit of thoraco-abdominal approach is still controversial. We evaluated the two approaches in a prospective randomized trial.

Interventions

PROCEDURESurgery: abdominal and transhiatal approach
PROCEDURESurgery: left thoraco-abdominal approach

Sponsors

Ministry of Health, Labour and Welfare, Japan
CollaboratorOTHER_GOV
Japan Clinical Oncology Group
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 75 Years
Healthy volunteers
No

Inclusion criteria

1. histologically proven adenocarcinoma 2. 75 years old or younger 3. forced expiratory volume in one second ≥ 50 % 4. arterial oxygen pressure in room air ≥ 70 mmHg 5. clinically T2/T3/T4 with ≤3 cm esophageal invasion 6. written consent

Exclusion criteria

1. Carcinoma in the remnant stomach 2. Borrmann type 4 (linitis plastica) 3. synchronous or metachronous malignancy in other organs except for cervical carcinoma in situ and colorectal focal cancer in adenoma 4. history of left thoracotomy, or left pleural adhesion 5. past history of myocardial infarction or positive results of exercise ECG 6. liver cirrhosis, or chronic liver disease with indocyanine green test ≥15%

Design outcomes

Primary

MeasureTime frame
overall survival

Secondary

MeasureTime frame
relapse-free survival
operative morbidity and mortality
quality of life

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 11, 2026